← Latest news 
Orchid Pharma rebounds as its first novel antibiotic wins US and EU approvals
Business
Published on 24 April 2026
Invented in 2008, the drug only now earns FDA and EU nods
Orchid Pharma, once abandoned by investors, is hitting a major milestone with its first novel antibiotic drug. The company outlicensed the experimental therapy to Germany’s Allecra Therapeutics, which has now secured crucial approvals from the US FDA and a European drug regulator. Developed by Indian scientists in 2008, the breakthrough aims to strengthen the global fight against bacterial infections.
- Orchid Pharma’s outlicensed antibiotic gained US FDA and EU approvals
- The drug traces back to research work by Indian scientists in 2008
- Milestone strengthens efforts against bacterial infections globally
- Allecra Therapeutics in Germany holds the approvals after years of development
Read the full story at The Economic Times
This summarization was done by Beige for a story published on 
The Economic Times